Delivery Order SPE2DB24D2101-SPE2DB25FKMPH
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,137.56 to AmerisourceBergen Drug Corp for the supply of Telmisartan 40 mg tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $4,630.31 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Telmisartan 40 mg tablets (30-count units) on August 18, 2025, with completion targeted for August 19, 2025. This non-set-aside contract was competitively awarded to the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania. The delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Telmisartan-HCZ 80-25 mg tablets (unit dose, 30-count packages) valued at $3,031.71. This non-set-aside, competitively awarded delivery order, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a firm fixed-price pharmaceutical supply transaction supporting federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $1,029.32 to AmerisourceBergen Drug Corp for the supply of Telmisartan 40 mg tablets (30-count) on August 21, 2025, with a completion date of August 22, 2025. This non-set-aside, competitively awarded contract employs firm fixed price terms and designates AmerisourceBergen's Conshohocken, Pennsylvania location as the place of performance. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Telmisartan 40 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $3,555.12. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999.99 billion and extending through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $3,006.30 to AmerisourceBergen Drug Corp for the supply of Telmisartan 80 mg tablets (30-count units) under a firm fixed price contract. The award, issued on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a non-set-aside competitive award. Performance of this delivery order will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This contract is a child order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Telmisartan 40 mg tablets (quantity 30) valued at $3,000.96. This competitive award, with no set-aside designation, represents a firm fixed-price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX, valued at $999,999,999.00 through December 2026). The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $1,093.50 to AmerisourceBergen Drug Corp for the supply of Telmisartan 40 mg tablets (30-count packaging) on August 14, 2025, with completion scheduled for August 15, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Telmisartan 80 mg tablets (30-count packages) under a firm fixed-price contract valued at $3,808.62. This competitive award, issued on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a child delivery order executed against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is located at the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $1,258.98 to AmerisourceBergen Drug Corp for the supply of Telmisartan 40 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The contract represents a single transaction under AmerisourceBergen's...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKMPHDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Telmisartan 40 mg tablets (30-count) under a firm fixed-price contract valued at $1,344.40. The award was issued on July 22, 2025, with an ultimate completion date of July 23, 2025. This delivery order represents a non-set-aside competitive award and is part of a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) relationship with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a primary pharmaceutical distributor for federal medical procurement and serves as a critical vendor for military and veteran healthcare systems. The company's performance location is listed as Conshohocken, PA 19428. This delivery order exemplifies AmerisourceBergen's role in supporting the DLA's comprehensive pharmaceutical supply chain, delivering essential medications to Defense Health Agency and other federal healthcare systems. The company's extensive portfolio with DLA encompasses brand-name and generic pharmaceuticals, vaccines, and specialized medical supplies across multiple therapeutic categories, demonstrating its capability to fulfill diverse federal medical supply requirements through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 7/22/25 |